Synthesis of [3-C-13]-2,3-dihydroxy-4-methoxybenzaldehyde by Collins, R.C. et al.
This is an author produced version of Synthesis of 
[3-C-13]-2,3-dihydroxy-4-methoxybenzaldehyde.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/96467/
Article:
Collins, R.C., Paley, M.N., Tozer, G.M. et al. (1 more author) (2016) Synthesis of 
[3-C-13]-2,3-dihydroxy-4-methoxybenzaldehyde. Tetrahedron Letters, 57 (5). pp. 563-565. 
ISSN 0040-4039 
https://doi.org/10.1016/j.tetlet.2015.12.088
promoting access to
White Rose research papers
eprints@whiterose.ac.uk
http://eprints.whiterose.ac.uk/
1 
 
Graphical abstract 
 
2 
 
Synthesis of [3-13C]-2,3-dihydroxy-4-methoxybenzaldehyde 
Rebecca C. Collins,1 Martyn N. Paley,2 Gillian M. Tozer3 and Simon Jones1 
1 Department of Chemistry, Dainton Building, University of Sheffield, Brook Hill, Sheffield. S3 7HF. UK 
2
 Academic Unit of Radiology, Department of Infection, Immunity & Cardiovascular Disease, The Medical 
School, The University of Sheffield, Beech Hill Road, Sheffield. S10 2RX 
3
 Department of Oncology & Metabolism, The Medical School, The University of Sheffield, Beech Hill Road, 
Sheffield. S10 2RX 
 
Abstract: An efficient synthesis of [3-13C]-2,3-dihydroxy-4-methoxybenzaldehyde, an isotopically labelled 
probe of a common intermediate used in the synthesis of a number of biologically relevant molecules, has been 
achieved in 9 steps from an acyclic, non-aromatic precursor. A 13C label for molecular imaging was introduced 
in a linear synthesis from the reaction of [13C]-labelled methyl iodide with glutaric monomethyl ester chloride. 
Cyclisation then aromatisation gave 1,3-dimethoxybenzene and an additional methoxy group was introduced by 
a formylation/Baeyer-Villiger/hydrolysis/methylation sequence. Subsequent ortho-formylation and selective 
demethylation yielded the desired [3-13C]-2,3-dihydroxy-4-methoxybenzaldehyde. 
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2,3-Dihydroxy-4-methoxybenzaldehyde 1 can be used as a key intermediate in a number of natural 
products/drugs that have a range of biological activities (Figure 1), including the vascular disrupting agents 
CA1P 2 and BNC 105P 3 that are currently in Phase I and II clinical trials, respectively.1±3 Another anti-cancer 
compound that can use this compound as a key intermediate is narciclasine 4,4 shown in vivo to be effective 
against primary brain cancers and brain metastases.5 Amongst other molecules of interesting biological 
properties, thalimonine 5 is a natural product that has shown to be active against influenza and herpes simplex 
virus,6±8 whilst stenocepflavone 6 exhibits significant inhibitory activity against acetylcholinesterase, 
butyrylcholinesterase and lipoxygenases,9 and 2'-hydroxy-3',4',3,4-tetramethoxychalcone 7 shows a topical anti-
inflammatory effect in mice.10 Whilst the biological activity of such compounds is usually easy to obtain, real-
time molecular imaging can provide vital information on molecular targets and the metabolic fates of 
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biologically active species. Dynamic nuclear polarization (DNP) is a hyperpolarization based magnetic 
resonance technique that can significantly increase the sensitivity of 13C nuclei;11 when used in conjunction with 
specifically labelled 13C samples, the relative sensitivity is further increased, allowing in vivo metabolism to be 
investigated.  
 
Figure 1. Potential natural products derived from key intermediate 1 
 
The design criteria for a 13C labelled probe for use in DNP studies is critical, since this needs to be at a site in 
the molecule with a long T1 relaxation time (essential for extending the lifetime of hyperpolarization), ideally on 
a quaternary centre remote from any neighboring spin ½ nuclei, which cannot undergo any destructive 
metabolism that would remove the label from the probe. Furthermore, the label need to be located at a site 
where metabolic activity occurs in order to observe a change in the chemical shift of the enhanced 13C signal 
that would be indicative of any new metabolite formed. For example, combretastatin A1P 2 is known to 
metabolise into ortho-quinone species 8 and 9 in vivo (Scheme 1), but the biological role of this metabolite has 
not yet been established.12 The chemical shift of the highlighted 13C in CA1P 2 is significantly lower than that 
on the same site in the ortho-quinone metabolite 9 [Gc (ppm) 136.7 vs. 178.9],13,14 so by hyperpolarising [13C]-
CA1P 2, signals for both species can easily be distinguished. Thus development of an efficient route to prepare 
[3-13C]-2,3-dihydroxy-4-methoxybenzaldehyde 1 would provide an avenue to prepare and investigate real-time 
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biological processes for these molecules of potential therapeutic interest. Furthermore, routes to pyrogallol 
derivatives of this type with site-specific incorporation of an aromatic 13C label have not been reported. 
 
Scheme 1. Known ortho-quinone metabolites of CA1P 2 
 
The synthesis of [3-13C]-2,3-dihydroxy-4-methoxybenzaldehyde 1 started with the installation of the 13C label 
by modifying an existing literature method.15 In this work, Botting and co-workers treated glutaric monomethyl 
ester chloride 10 with [13C]-lithium dimethyl cuprate, generated from [13C]-methyl iodide, lithium, and copper(I) 
iodide, which resulted in formation of methyl 5-oxo-[6-13C]-hexanoate 11 in 43% yield. However, in the route 
developed herein, an improved yield of 55% for the ester 11 was obtained when the acid chloride 10 was treated 
with [13C]-methyl magnesium iodide and copper(I) bromide dimethyl sulfide, where the [13C] labelled Grignard 
reagent was accessed from commercially available [13C]-methyl iodide (Scheme 2). This method was found to 
be highly reproducible and easier to operate than the original cuprate procedure. Furthermore, this method 
circumvents the sometimes difficult generation of [13C]-labelled methyl lithium and uses stoichiometric 
quantities of [13C]-methyl iodide, rather than losing an additional unreactive equivalent through the cuprate. 
Cyclisation of methyl 5-oxo-[6-13C]-hexanoate 11 to [2-13C]-cyclohexane-1,3-dione 12 was achieved in 61% 
yield via an intramolecular Claisen reaction using potassium tert-butoxide as the base. The product was 
observed as a mixture of both keto and enol tautomers in the 1H NMR spectrum. Aromatisation of [2-13C]-
cyclohexane-1,3-dione 12 to give [2-13C]-resorcinol has previously been achieved by catalytic dehydrogenation 
using Pd/C in refluxing xylene or triglyme with yields ranging from 45 ± 88%.16±18 However, an alternate, more 
efficient route was developed that encompassed both the aromatisation and subsequent methylation steps in a 
one-pot reaction. Thus, dione 12 was heated at reflux with iodine in methanol to give the aromatised 1,3-
dimethoxy-[2-13C]-benzene 13 in 67% yield.19 Next, the regioselective addition of a hydroxyl group in the 2-
position was accomplished using a three-step strategy. Regioselective lithiation of 1,3-dimethoxy-[2-13C]-
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benzene 13 with nBuLi at 0 °C in the presence of N,N,NƍNƍ-tetramethylethylenediamine followed by treatment 
with dimethylformamide and gave [1-13C]-2,6-dimethoxybenzaldehyde 14 in 89% yield.20 This was then treated 
with hydrogen peroxide in methanol to affect a Baeyer-Villiger reaction but unfortunately this failed to yield the 
desired formate ester, instead giving carboxylic acid 15 in a 2:1 ratio with starting material, formed by hydride-
migration in the rearrangement step of the Baeyer-Villiger reaction. However, when aldehyde 14 was treated 
with mCPBA, the desired formate ester was formed, which was hydrolyzed using potassium hydroxide to give 
phenol 16 in 84% yield over the three-steps from methyl ether 13.  
 
Scheme 2. Synthesis of [2-13C]-2-hydroxy-1,3-methoxybenzene 16 
 
[2-13C]-2,6-Dimethoxyphenol 16 was then methylated using potassium carbonate and methyl iodide to yield [2-
13C]-1,2,3-trimethoxybenzene 17 in 80% yield, that underwent ortho-formylation using Rieche conditions 
(titanium tetrachloride and dichloromethyl methyl ether) to give the aldehyde 18 in 71% yield (Scheme 3). 
Treatment of [3-13C]-2,3,4-trimethoxybenzaldehyde 18 with two equivalents of boron trichloride led to selective 
demethylation of the methyl ethers ortho and meta to the carbonyl group, providing [3-13C]-2,3-dihydroxy-4-
methoxybenzaldehyde 1 in 84% yield. The regiochemistry of this deprotection was confirmed by correlation of 
the 13C NMR data with previously reported unlabeled material, with all chemical shifts matching to within 0.3 
ppm.21 
 
Scheme 3. Synthesis of [3-13C]-2,3-hydroxy-4-methoxybenzaldehyde 4 
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In summary, we have adapted and developed an efficient route to install a 13C label at a strategically important 
site of a common intermediate that can be used to construct a number of biologically relevant molecules. 
Ongoing work is looking to exemplify the use of such an intermediate in the synthesis of the target molecules 
illustrated. 
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